Q4FY26- Revlimid void, one-off costs hurt numbers; Outlook optimisticQ4FY26 revenues de-grew 11.5% YoY to 7546.4 crore, pulled down significantly by the US business which de-grew 51% YoY to 1756 crore and PSAI which de-grew 4.5% YoY to 912 crore. The US business declined on account of lower gRevlimid sales and a one-time Shelf Stock Adjustment (SSA) of ~453 crore. The de-growth in US was stabilized by growth in other key geographies. Europe grew 14% YoY to 1452 crore (NRT portfolio in Europe grew 16% YoY to ~695 crore), India Business grew 20% YoY to 1566.3 crore, Russia and Other CIS business grew 19%...